| |
|
|
|
|
| January 14,
2010 | ISSUE NUMBER 131 VOL 8 |
Events
JP Morgan Healthcare Conference Marked by Hesitant Optimismt
While last year’s meeting was dominated by the global economic crisis and its impact on the healthcare industry, this year’s presenters tried to give investors a glimmer of hope for better outcomes in the future.
Pricing
GAO Seeks Price Spike Explanation
At time when people can’t even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government’s General Accountability Office examines why drug products took a massive price leap in recent years.
Regulatory
FDA Basics Brings the Agency Out of the Closet
The push for government transparency continues with Phase I of FDA’s plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs.
Strategy
Cold Cuts: Merck Layoffs Loom
That frigid feeling is not just the weather, as Merck & Co. ponders some cold hard decisions. Following on the heels of its now-closed acquisition of Schering-Plough, Merck is making significant job cuts across its operations.
New & Noteworthy
Strategy for Security
A new pharma consortium focuses on securing the supply chain upstream. Pharm Exec interviews Rx360 to learn more.
|
 |
|  Biostar Pharmaceuticals appointed two independent directors, Zibing "Zack" Pan and Zhongyang Shang, to its board
// Pieris AG appointed Stephen S. Yoder as CEO
// GeoVax Labs added Mark J. Newman as VP, research and development
// Diffusion Pharmaceuticals hired David R. Jones as chief medical officer and member of its scientific advisory board
// MacroGenics appointed Anastasia Daifotis senior VP, clinical development
// Dan Schultz joined Greenleaf Health as senior VP, medical devices and combo products
// Clavis Pharma hired Olav Hellebo as CEO.
// Inovio Biomedical named Mark Bagarazzi as chief medical officer
// Biogen added Carol Dorsa to its board
// Genzyme hired Ron Branning as senior VP of global product quality
// Prolong Pharmaceuticals appointed Richard Prince VP, quality
// Sanofi-Aventis hired Hans Regenauer as group VP, consumer health, Europe
// Crescendo Biologics appointed Clive Dix as Chairman
// Peregrine Pharmaceuticals appointed Marvin R. Garovoy as head of clinical science.
// Jennerex added Dr. Hoyoung Huh to Its board of directors.
//
|
|
|
Jan 21–22, 2010 Bio/Pharmaceutical Forum on Optimizing the Use of Complex Data Assets,
Philadelphia, PA
Jan 25–26, 2010 Pharmaceutical Forum on Strategic Sourcing and Procurement,
Philadelphia, PA
Feb 8–9, 2010 3rd Annual Clinical Trial Forecasting and Budgeting, Philadelphia, PA
Feb 23 –25, 2010 BIO-Windhover/Pharmaceutical Strategic Outlook, New York, NY
April 12–14, 2010 19th Annual Partnerships in Clinical Trials, Orlando FL
|
|
|
|
 |
|
 |
|
 |
| Is Novartis making a smart move in purchasing Alcon? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe
from this list click
here.
To
ensure delivery to your Inbox, please add %%email.list%% to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
